$2.47
+0.07 (+2.92%)
Open$2.41
Previous Close$2.40
Day High$2.49
Day Low$2.39
52W High$10.38
52W Low$2.26
Volume—
Avg Volume566.0K
Market Cap226.18M
P/E Ratio—
EPS$-0.15
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,108.5% upside
Current
$2.47
$2.47
Target
$29.85
$29.85
$17.55
$29.85 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |
| Rev Growth | +23.0% | -7.3% | -7.0% |
| Debt/Equity | 0.80 | 0.99 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |